tiprankstipranks
NervGen Pharma (DE:9UA)
FRANKFURT:9UA
Germany Market
9UA
NervGen Pharma
RESEARCH TOOLSreports

NervGen Pharma (9UA) Financial Statements

2 Followers

NervGen Pharma Financial Overview

NervGen Pharma's market cap is currently €130.60M. The company's EPS TTM is €-0.3659; its P/E ratio is -8.54; NervGen Pharma is scheduled to report earnings on May 15, 2026, and the estimated EPS forecast is €-0.06. See an overview of income statement, balance sheet, and cash flow financials.
Mar 26Mar 25Mar 24Dec 22Dec 21
Income Statement
Total RevenueC$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross ProfitC$ 0.00C$ -83.74KC$ -145.01KC$ -114.10KC$ -42.95K
Operating IncomeC$ -25.08MC$ -24.92MC$ -17.78MC$ -22.82MC$ -12.91M
EBITDAC$ -5.65MC$ -23.91MC$ -22.24MC$ -19.92MC$ -12.78M
Net IncomeC$ -44.12MC$ -23.99MC$ -22.38MC$ -20.54MC$ -12.82M
Balance Sheet
Cash & Short-Term InvestmentsC$ 22.07MC$ 17.35MC$ 11.66MC$ 22.25MC$ 17.06M
Total AssetsC$ 23.21MC$ 19.47MC$ 13.24MC$ 23.67MC$ 18.03M
Total DebtC$ 8.37KC$ 105.53KC$ 197.21KC$ 280.96KC$ 0.00
Net DebtC$ -22.06MC$ -17.15MC$ -11.46MC$ -21.97MC$ -17.06M
Total LiabilitiesC$ 19.73MC$ 16.90MC$ 15.25MC$ 10.32MC$ 1.09M
Stockholders' EquityC$ 3.48MC$ 2.57MC$ -2.01MC$ 13.34MC$ 16.95M
Cash Flow
Free Cash FlowC$ -19.50MC$ -16.83MC$ -11.30MC$ -17.65MC$ -8.33M
Operating Cash FlowC$ -19.50MC$ -16.83MC$ -11.30MC$ -17.63MC$ -8.33M
Investing Cash FlowC$ 100.93KC$ 58.83KC$ -138.87KC$ -20.92KC$ -45.43K
Financing Cash FlowC$ 23.76MC$ 22.68MC$ 766.35KC$ 22.44MC$ 19.76M
Currency in CAD

NervGen Pharma Earnings and Revenue History

Income Statement >

NervGen Pharma Debt to Assets

Balance Sheet >

NervGen Pharma Cash Flow

Cash Flow >

NervGen Pharma Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
Earnings >